Business Context and Reporting Period
SEALSQ Corp, a British Virgin Islands company reporting as a foreign private issuer on Form 20-F, filed this Form 6-K on January 12, 2024. The filing reports the January 9, 2024 closing of a second tranche of convertible notes and warrants under an amended securities purchase agreement originally entered into on July 11, 2023.
Transaction and Key Financial Metrics
- Second tranche financing: $10.0 million aggregate principal amount of 4% senior original issue discount convertible notes due 2026.
- Net proceeds before expenses: Approximately $9.6 million, reflecting a 4% original issue discount.
- Warrants: Warrants exercisable for up to 2,288,678 ordinary shares, with a five-year maturity and an initial exercise price of $4.00 per share.
- Note conversion terms: The conversion price is the lesser of $4.00 per share or 92% of the lowest volume-weighted average price during the preceding 10 trading days, subject to a $0.55 floor that may be lowered by mutual consent and customary anti-dilution adjustments.
- Share reserve: The Company must reserve 45,000,000 ordinary shares for issuance under the second tranche.
- First tranche conversions: Investors had converted $9.5 million of first tranche notes into 9,249,257 ordinary shares. The remaining $500,000 could result in up to 588,235 additional shares if converted at the then-current $0.85 floor price.
- Shares outstanding: 16,758,941 ordinary shares as of the filing date, before any further potential issuances described in the filing.
The filing does not provide revenue, profit, cash flow, operating margin, cash balance, total debt, or liquidity metrics for a comparable reporting period.
Material Changes Versus the Prior Comparable Period
- The Company completed a second $10.0 million financing tranche, adding notes due 2026 and warrants for 2,288,678 shares.
- For the second tranche, the fixed conversion and warrant exercise price was reduced from $30.00 to $4.00, and the conversion floor was reduced from $2.50 to $0.55.
- The investors waived, solely for the second tranche, certain restrictions on additional indebtedness. Permitted indebtedness includes the first and second tranche notes, up to $2.0 million payable to Cisco Systems, Inc., and qualifying affiliate loans subject to stated limitations.
- The Company and investors agreed to investor resale limitations generally targeting no more than 15% of average weekly trading volume for converted shares, subject to exceptions and waivers.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- A potential third tranche of up to $10.0 million in additional notes may be issued only with mutual consent, satisfaction or waiver of closing conditions, and effectiveness of the required registration statement. No third tranche had closed as of the filing date.
- The Company is required to file a registration statement covering resale of shares issuable upon conversion of the second tranche notes and exercise of the second tranche warrants within 20 trading days after the January 9, 2024 closing. It intends to obtain effectiveness as soon as practicable and, if subject to SEC review, no later than 75 days after closing.
- If an effective registration statement is not available six months after closing, the second tranche warrants may be exercisable on a cashless basis.
- The variable conversion mechanism, low conversion floor, warrant issuance, anti-dilution protections, and required share reserve could result in substantial dilution to existing shareholders.
- The filing does not provide management earnings guidance or an operating outlook.
Important Facts for Investors to Verify
- Whether the required registration statement was filed and declared effective within the stated deadlines.
- Actual conversion activity under both the first and second tranche notes and the resulting ordinary-share count.
- Whether the potential third tranche was approved or closed and on what terms.
- The Company’s current cash, liquidity, total indebtedness, and ability to meet note obligations, which are not provided in this filing.
- The full terms of the amendment, notes, warrants, and registration rights agreement attached as Exhibits 10.1 through 10.3.